This pipeline uses various statistical tests to identify mRNAs whose expression levels correlated to selected clinical features.
Testing the association between 18310 genes and 12 clinical features across 354 samples, statistically thresholded by Q value < 0.05, 7 clinical features related to at least one genes.
-
6 genes correlated to 'Time to Death'.
-
ESYT3|83850 , UCN2|90226 , PPP1R3G|648791 , B3GNT8|374907 , LOC645166|645166 , ...
-
3 genes correlated to 'AGE'.
-
HSD17B2|3294 , GPR15|2838 , AHRR|57491
-
85 genes correlated to 'GENDER'.
-
PRKY|5616 , ZFY|7544 , RPS4Y1|6192 , XIST|7503 , DDX3Y|8653 , ...
-
30 genes correlated to 'HISTOLOGICAL.TYPE'.
-
CREB3L3|84699 , A4GNT|51146 , REG4|83998 , MIA|8190 , CRH|1392 , ...
-
2 genes correlated to 'YEAROFTOBACCOSMOKINGONSET'.
-
GPR15|2838 , ENTPD3|956
-
53 genes correlated to 'DISTANT.METASTASIS'.
-
CUL4A|8451 , AMFR|267 , SEZ6|124925 , DCUN1D2|55208 , PROZ|8858 , ...
-
1 gene correlated to 'LYMPH.NODE.METASTASIS'.
-
AKR1D1|6718
-
No genes correlated to 'KARNOFSKY.PERFORMANCE.SCORE', 'RADIATIONS.RADIATION.REGIMENINDICATION', 'NUMBERPACKYEARSSMOKED', 'COMPLETENESS.OF.RESECTION', and 'NEOPLASM.DISEASESTAGE'.
Complete statistical result table is provided in Supplement Table 1
Clinical feature | Statistical test | Significant genes | Associated with | Associated with | ||
---|---|---|---|---|---|---|
Time to Death | Cox regression test | N=6 | shorter survival | N=3 | longer survival | N=3 |
AGE | Spearman correlation test | N=3 | older | N=1 | younger | N=2 |
GENDER | t test | N=85 | male | N=29 | female | N=56 |
KARNOFSKY PERFORMANCE SCORE | Spearman correlation test | N=0 | ||||
HISTOLOGICAL TYPE | ANOVA test | N=30 | ||||
RADIATIONS RADIATION REGIMENINDICATION | t test | N=0 | ||||
NUMBERPACKYEARSSMOKED | Spearman correlation test | N=0 | ||||
YEAROFTOBACCOSMOKINGONSET | Spearman correlation test | N=2 | higher yearoftobaccosmokingonset | N=1 | lower yearoftobaccosmokingonset | N=1 |
DISTANT METASTASIS | ANOVA test | N=53 | ||||
LYMPH NODE METASTASIS | ANOVA test | N=1 | ||||
COMPLETENESS OF RESECTION | ANOVA test | N=0 | ||||
NEOPLASM DISEASESTAGE | ANOVA test | N=0 |
Time to Death | Duration (Months) | 0-224 (median=9.4) |
censored | N = 236 | |
death | N = 83 | |
Significant markers | N = 6 | |
associated with shorter survival | 3 | |
associated with longer survival | 3 |
HazardRatio | Wald_P | Q | C_index | |
---|---|---|---|---|
ESYT3|83850 | 0.72 | 1.342e-07 | 0.0025 | 0.368 |
UCN2|90226 | 1.36 | 3.136e-07 | 0.0057 | 0.638 |
PPP1R3G|648791 | 1.54 | 5.393e-07 | 0.0099 | 0.66 |
B3GNT8|374907 | 0.71 | 9.262e-07 | 0.017 | 0.334 |
LOC645166|645166 | 1.5 | 1.473e-06 | 0.027 | 0.652 |
MYLIP|29116 | 0.51 | 1.735e-06 | 0.032 | 0.354 |
AGE | Mean (SD) | 65.2 (9.8) |
Significant markers | N = 3 | |
pos. correlated | 1 | |
neg. correlated | 2 |
SpearmanCorr | corrP | Q | |
---|---|---|---|
HSD17B2|3294 | 0.2704 | 1.068e-06 | 0.0196 |
GPR15|2838 | -0.2676 | 2.494e-06 | 0.0457 |
AHRR|57491 | -0.2582 | 2.67e-06 | 0.0489 |
GENDER | Labels | N |
FEMALE | 191 | |
MALE | 163 | |
Significant markers | N = 85 | |
Higher in MALE | 29 | |
Higher in FEMALE | 56 |
T(pos if higher in 'MALE') | ttestP | Q | AUC | |
---|---|---|---|---|
PRKY|5616 | 45.81 | 3.572e-142 | 6.54e-138 | 0.9994 |
ZFY|7544 | 53.94 | 1.054e-117 | 1.93e-113 | 0.998 |
RPS4Y1|6192 | 49.02 | 1.536e-97 | 2.81e-93 | 0.9967 |
XIST|7503 | -36.21 | 1.936e-86 | 3.54e-82 | 0.9809 |
DDX3Y|8653 | 46.36 | 2.005e-66 | 3.67e-62 | 0.9976 |
KDM5D|8284 | 39.96 | 2.039e-51 | 3.73e-47 | 0.9984 |
NLGN4Y|22829 | 27.19 | 2.454e-50 | 4.49e-46 | 0.9914 |
USP9Y|8287 | 39.66 | 1.149e-48 | 2.1e-44 | 0.9996 |
TSIX|9383 | -18.52 | 4.287e-36 | 7.84e-32 | 0.9721 |
UTY|7404 | 27.19 | 4.833e-26 | 8.84e-22 | 0.9959 |
No gene related to 'KARNOFSKY.PERFORMANCE.SCORE'.
KARNOFSKY.PERFORMANCE.SCORE | Mean (SD) | 75.86 (32) |
Significant markers | N = 0 |
HISTOLOGICAL.TYPE | Labels | N |
LUNG ACINAR ADENOCARCINOMA | 10 | |
LUNG ADENOCARCINOMA MIXED SUBTYPE | 75 | |
LUNG ADENOCARCINOMA- NOT OTHERWISE SPECIFIED (NOS) | 214 | |
LUNG BRONCHIOLOALVEOLAR CARCINOMA MUCINOUS | 4 | |
LUNG BRONCHIOLOALVEOLAR CARCINOMA NONMUCINOUS | 17 | |
LUNG CLEAR CELL ADENOCARCINOMA | 2 | |
LUNG MICROPAPILLARY ADENOCARCINOMA | 3 | |
LUNG MUCINOUS ADENOCARCINOMA | 2 | |
LUNG PAPILLARY ADENOCARCINOMA | 17 | |
LUNG SOLID PATTERN PREDOMINANT ADENOCARCINOMA | 3 | |
MUCINOUS (COLLOID) CARCINOMA | 7 | |
Significant markers | N = 30 |
ANOVA_P | Q | |
---|---|---|
CREB3L3|84699 | 7.21e-12 | 1.32e-07 |
A4GNT|51146 | 1.532e-11 | 2.81e-07 |
REG4|83998 | 2.013e-10 | 3.68e-06 |
MIA|8190 | 3.384e-09 | 6.19e-05 |
CRH|1392 | 4.05e-09 | 7.41e-05 |
ELOVL5|60481 | 5.324e-09 | 9.75e-05 |
DPCR1|135656 | 7.733e-09 | 0.000142 |
FER1L6|654463 | 9.555e-09 | 0.000175 |
DNAH14|127602 | 2.68e-08 | 0.000491 |
LRRC66|339977 | 3.51e-08 | 0.000642 |
No gene related to 'RADIATIONS.RADIATION.REGIMENINDICATION'.
RADIATIONS.RADIATION.REGIMENINDICATION | Labels | N |
NO | 17 | |
YES | 337 | |
Significant markers | N = 0 |
NUMBERPACKYEARSSMOKED | Mean (SD) | 41.04 (27) |
Significant markers | N = 0 |
YEAROFTOBACCOSMOKINGONSET | Mean (SD) | 1965 (13) |
Significant markers | N = 2 | |
pos. correlated | 1 | |
neg. correlated | 1 |
SpearmanCorr | corrP | Q | |
---|---|---|---|
GPR15|2838 | 0.365 | 7.932e-07 | 0.0145 |
ENTPD3|956 | -0.3493 | 1.097e-06 | 0.0201 |
DISTANT.METASTASIS | Labels | N |
M0 | 242 | |
M1 | 17 | |
M1A | 1 | |
M1B | 3 | |
MX | 87 | |
Significant markers | N = 53 |
ANOVA_P | Q | |
---|---|---|
CUL4A|8451 | 5.538e-11 | 1.01e-06 |
AMFR|267 | 1.429e-09 | 2.62e-05 |
SEZ6|124925 | 3.019e-09 | 5.53e-05 |
DCUN1D2|55208 | 3.594e-09 | 6.58e-05 |
PROZ|8858 | 4.698e-09 | 8.6e-05 |
MGMT|4255 | 6.505e-09 | 0.000119 |
SLC35F2|54733 | 6.883e-09 | 0.000126 |
MLL5|55904 | 1.02e-08 | 0.000187 |
C3ORF42|84657 | 4.222e-08 | 0.000773 |
TMCO3|55002 | 4.42e-08 | 0.000809 |
LYMPH.NODE.METASTASIS | Labels | N |
N0 | 218 | |
N1 | 71 | |
N2 | 55 | |
N3 | 1 | |
NX | 7 | |
Significant markers | N = 1 |
ANOVA_P | Q | |
---|---|---|
AKR1D1|6718 | 1.059e-08 | 0.000194 |
COMPLETENESS.OF.RESECTION | Labels | N |
R0 | 213 | |
R1 | 9 | |
R2 | 4 | |
RX | 12 | |
Significant markers | N = 0 |
-
Expresson data file = LUAD-TP.uncv2.mRNAseq_RSEM_normalized_log2.txt
-
Clinical data file = LUAD-TP.clin.merged.picked.txt
-
Number of patients = 354
-
Number of genes = 18310
-
Number of clinical features = 12
For survival clinical features, Wald's test in univariate Cox regression analysis with proportional hazards model (Andersen and Gill 1982) was used to estimate the P values using the 'coxph' function in R. Kaplan-Meier survival curves were plot using the four quartile subgroups of patients based on expression levels
For continuous numerical clinical features, Spearman's rank correlation coefficients (Spearman 1904) and two-tailed P values were estimated using 'cor.test' function in R
For two-class clinical features, two-tailed Student's t test with unequal variance (Lehmann and Romano 2005) was applied to compare the log2-expression levels between the two clinical classes using 't.test' function in R
For multi-class clinical features (ordinal or nominal), one-way analysis of variance (Howell 2002) was applied to compare the log2-expression levels between different clinical classes using 'anova' function in R
For multiple hypothesis correction, Q value is the False Discovery Rate (FDR) analogue of the P value (Benjamini and Hochberg 1995), defined as the minimum FDR at which the test may be called significant. We used the 'Benjamini and Hochberg' method of 'p.adjust' function in R to convert P values into Q values.
This is an experimental feature. The full results of the analysis summarized in this report can be downloaded from the TCGA Data Coordination Center.